Abstract
Background: The EGF-based vaccine, commercially known as CIMAvax-EGF®, consists of a chemical conjugate of the epidermal growth factor (EGF) with the P64 protein derived from the Meningitis B bacteria and the Montanide ISA 51, as adjuvant. The vaccine induces antibodies against EGF that results in EGF castration. CIMAvax-EGF has been demonstrated to be safe and immunogenic in advanced NSCLC patients and more recently in non-invasive bladder cancer patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
